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This review will focus primarily on the aspects that 
surround the decision to undertake liver trans­
plantation in a child with acute liver failure (ALF). 
There are many excellent chapters and journal reviews 
that cover specific medical management of ALF and 
its complications; therefore this will not be addressed in this article. 
Definition of ALF
Using the traditional definition of ALF, being the onset of hepatic 
encephalopathy within 8 weeks of the onset of liver disease, may 
present several challenges, not least because encephalopathy in 
children is difficult to assess, may be present in acute conditions 
other than liver failure, and is commonly a late manifestation 
that may not even be detected prior to the occurrence of death or 
transplantation. The entry criteria for the Pediatric ALF (PALF) study 
set the bar low (i.e. international normalised ratio (INR) >2.0 without 
encephalopathy or >1.5 with encephalopathy), not in an attempt to 
redefine ALF but in order to recruit subjects in the early stages of a 
disease, who may progress to full­blown liver failure.[1] 
Understanding the manifestations and determining the clinical 
characteristics in the early stages of the disease may be crucial in 
developing the necessary effective prognostic tools. For the non­
specialist centre where acute hepatitis may be a common occurrence, 
it is difficult to determine when a patient justifies transfer to a liver 
transplant centre. This is particularly challenging if the distance of 
the tertiary centre from home is large and if resources within any 
given health system are limited. The entry criteria for the PALF study 
would seem to be a good starting point. If a patient has an INR >2.0 
due to acute liver disease or liver disease with encephalopathy and a 
lesser degree of coagulopathy, referral to a transplant centre should 
be initiated. This does not mean that patients with an INR of 2.0 
and new­onset liver disease should be listed immediately for liver 
transplantation, but waiting until the patient categorically needs 
a transplant would be to leave no time for work­up, listing and 
identification of a usable allograft. 
Diagnostic work-up of a child with ALF 
The causes of ALF are protean (Table 1), but we should be aware 
of the range of causes within our own patient populations. Often, 
diagnostic work­ups are incomplete even in the context of a well­
funded multicentre study.[2] A systematic approach using standard 
protocols and computerised order sets may be the safest way of 
avoiding omissions during a diagnostic work­up, although this 
approach may lack focus based on specific clinical findings and lead 
to unnecessary tests that waste limited resources. 
In general terms, diagnostic priorities include the common diseases 
and those conditions significantly serious that they should be ruled 
out early, with second­ and even third­line investigations of less likely 
conditions thereafter. However, in ALF, the life­threatening nature 
of almost any potential diagnosis, along with the time constraints 
imposed by a progressive disease, necessitate a complete work­up at 
the outset (Table 2). 
Many institutions have implemented blood draw limits based 
on the weight of the child for routine and research testing, but it is 
important to remember that these are guidelines and that a full work­
up should be undertaken even if this requires blood transfusion once 
the appropriate blood samples have been drawn. 
Indications for liver transplantation  
in a child with ALF 
Survival from ALF in children, as in adults, has been transformed by 
liver transplantation, but the precise indications for liver transplant 
remain contentious, especially in children.[3,4] Decisions are made on 
the basis of readily available data, including the clinical condition, 
presence of encephalopathy and cerebral oedema, diagnosis, age of 
patient, duration of illness, level of jaundice and various measures of 
coagulation, and possibly ammonia, ­fetoprotein, lactate and plasma 
phosphate levels. Strict cut­off levels that precisely predict death or 
survival do not exist. 
Prognostic scores have been developed to assist decision­
making and for epidemiological descriptions, but there remains a 
need for clinical judgement in any decision to proceed with liver 
transplantation in children with ALF. Such judgements depend on 
dynamic assessments of the patient’s disease progression and not on 
a single set of laboratory measurements. 
Although the paediatric end­stage liver disease (PELD) scoring 
system was designed to evaluate severity and mortality risk for 
chronic liver disease in children, initial PELD scores at presentation 
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are significantly higher among non­survivors of ALF compared with 
survivors.[5] 
Outcomes of ALF in childhood
Before liver transplantation became an option, spontaneous survival 
from ALF in a cohort of children seen at King’s College Hospital 
in London was 28%, but only 4% in those who progressed to grade 
IV coma.[6] The difficulty with comparing these survival figures 
with current outcomes is not only the changes in care, but also in 
the definitions used for diagnosis. In the PALF cohort, outcome 
varied according to diagnosis, with the greatest transplant­free 
survival in acetaminophen toxicity and shock (94% and 81% at 21 
days, respectively).[1] Transplant­free survival was lowest in non­
acetaminophen, drug­induced hepatitis and also in those for whom a 
cause could not be determined (41% and 43%, respectively). With the 
exception of the acetaminophen group, transplant rates were in the 
range of 20 ­ 42%, with the highest rates in the indeterminate group. 
Liver transplantation for ALF accounted for 12.9% of all 
paediatric cases from 1995  to 2002 in the Studies in Pediatric Liver 
Transplantation (SPLIT) database.[3] Over a 3­year period, from 
2009  to  2011, there were 241 (14.4%) liver transplants in children 
listed at status 1A in the USA; this number also includes those who 
required emergency retransplantation for hepatic artery thrombosis 
and primary non­function.[7] Outcomes of liver transplantation for 
ALF have generally shown poorer survival than for chronic liver 
failure. In the early SPLIT experience from 1995 to 2002, there was 
a 74% 1­year patient survival rate for ALF compared with 88.2% for 
all other causes.[3] 
Farmer et al.[8] summarised the published literature and described 
1­year post­transplant survival in children with ALF as ranging from 
67% to 93%. On the basis of a multivariate analysis of data from the 
University of California, Los Angeles, these authors also suggested 
that predictors of patient survival after liver transplantation in 
children with ALF were: better renal function (calculated creatinine 
clearance >60  mL/min/1.73  m2); and a duration of jaundice to 
encephalopathy of >7 days. 
A series of children with ALF from Korea demonstrated a post­
transplant survival rate at 1 year of 87.9%, with the majority of this 
cohort (94%) having received living donor allografts.[9] 
At Seattle Children’s, 21 children have undergone orthotopic liver 
transplantation for ALF since January 2005. Patient and graft survival 
is 95.2%, with time since liver transplantation ranging from 45 days 
to almost 9 years (median 46 months). In two cases, a live donor was 
utilised, and in the deceased donor cases, blood groups were crossed 
in nine; two with compatible blood groups and seven with ABO­
incompatible grafts. A single death occurred at 8 days post­transplant 
in a 6­week­old infant with neonatal haemochromatosis.
Obstacles to optimal management of  
a paediatric patient with ALF
The ideal scenario would be to identify an aetiology and to start 
treatment expeditiously in those with diagnosable conditions. 
Diagnoses that are potentially treatable include autoimmune hepatitis, 
drug toxicity and certain infectious conditions. For those with a 
diagnosis for which an effective treatment is not available, or for those 
cases where the precise diagnosis continues to evade elucidation, a 
reliable prognostic indicator would determine whether the patient will 
progress to terminal stage or will improve with supportive therapy. 
To bridge patients either to recovery or to transplantation, effective 
support of liver function would prolong the time in which careful 
transplant work­up and identification of a suitable organ, either 
from a live or deceased donor, can take place. For those patients 
with irrecoverable liver failure and in whom the expectation of 
the native liver’s regenerative potential is negligible, orthotopic 
liver transplantation with total hepatectomy should be undertaken 
expeditiously. As with the majority of current transplant patients, 
these patients would need lifetime monitoring and long­term 
immunosuppression, but outcomes, both short­ and long­term, are 
now excellent in experienced centres. 
Table 1. Causes of acute liver failure in infants and children
Viral Hepatitis A
Hepatitis B
Hepatitis D
Hepatitis E
Herpes simplex
Varicella zoster virus
Epstein­Barr virus
Cytomegalovirus
Paramyxovirus
Adenovirus
Enterovirus
Parvovirus B19
Severe acute respiratory syndrome
Haemorrhagic fever viruses
Bacterial Septicaemia
Leptospirosis
Salmonella typhi/S. paratyphi
Bartonella
Rocky Mountain spotted fever
Metabolic Hereditary fructose intolerance
Urea cycle disorders
Organic acidaemias
Fatty acid oxidation defects 
Mitochondrial disorders
Carnitine defects
Wilson’s disease 
Tyrosinaemia type 1
Niemann­Pick disease type C
Acute fatty liver of pregnancy
Immune Autoimmune hepatitis
Haemophagocytic lymphohistiocytosis
Neonatal haemochromatosis
Autoimmune haemolytic anaemia with giant­
cell hepatitis
Toxic Drugs/toxins/herbals
Amanita phalloides
Vascular Budd­Chiari syndrome
Veno­occlusive disease
Ischaemic hepatitis/shock liver
Post cardiac surgery
Liver trauma
Neoplastic Leukaemia
Lymphoma
Hepatocellular carcinoma
Other Reye’s syndrome
Hypothermia
Heat stroke
Massive liver resection
Sickle cell anaemia
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There is also a group of patients in whom 
the liver has failed acutely, and survival can 
only be expected with the rapid return to 
normal hepatic function but in whom long­
term hepatic regenerative potential exists. 
This is most clear in those patients with 
severe acetaminophen overdose, but also 
includes patients with unknown and other 
specific causes, such as Amanita mushroom 
poisoning. Greater use of auxiliary 
transplantation might be envisaged in these 
situations. Thus, when supported through 
the acute illness, the native liver has the 
opportunity to regenerate and the auxiliary 
allograft can be allowed to gradually involute. 
Finally, there are some conditions where 
transplantation would be futile, such as a 
generalised mitochondrial cytopathy, in 
which cases optimal palliative care may be 
implemented.
Barriers to applying this approach abound. 
Worldwide, providers are confronted with: 
a lack of reliable prognostic tools; a lack 
of proven liver support techniques; ineffi­
cient transplant work­up and organ 
availability; and the application of auxiliary 
liver transplantation in only a very limited 
number of transplant centres. 
Prognostic tools
Numerous attempts have been made over the 
years to amalgamate clinical and laboratory 
data into models that will predict death without 
transplantation for patients with acute hepatic 
insufficiency. Examples include the King’s 
College Hospital criteria (KCHC), the Clichy 
score and the liver injury unit (LIU) score, but 
all have fallen well short of ideal.[4,10] Clinically, 
the majority of physicians are quite accurate 
at predicting death within an hour or two 
of the event, but 5 or 7 days (or maybe even 
longer) preceding the event is a completely 
different proposition. This time interval is 
required to safely list a patient for transplant 
and to find a suitable organ before the patient 
is in too perilous a state to achieve optimal 
outcomes from the subsequent transplant, 
or to be bold enough not to list a patient 
who may recover spontaneously. One of 
the difficulties may be that the dice are not 
necessarily cast at these temporally distant 
points. In adults with ALF, Bernal et al.[11] 
described an improvement in overall survival 
in ALF from 17% in the 1970s to 62% in 
the period 2004 ­ 2008, and even in those 
not undergoing transplantation, survival rose 
from 17% to 48%. With medical advances and 
the potential predictive power of any of the 
prognostic models in mind, care is modified, 
and thus the power to predict outcome 
diminishes. This is a recognised phenomenon 
in economics and politics whereby the more 
Table 2. Diagnostic work-up for infants and children with acute liver failure
Age for testing
Blood
Haematology Complete blood count with differential
PT/INR
Factor 5 level
Factor 7 level
Fibrinogen level 
ABO/rhesus typing
Biochemistry Electrolytes
Calcium, magnesium and phosphorus
BUN and creatinine
Glucose
Lactate and pyruvate
Bilirubin – conjugated and unconjugated
AST and ALT
GGT
Alkaline phosphatase
Albumin
Total protein
Uric acid
Lipase and amylase
Cholesterol and triglycerides
Ceruloplasmin 
Copper 
Ferritin
Zinc
Acylcarnitine profile 
Amino acid quantitative
Alpha­fetoprotein
Beta hCG 
Blood gases
Children ≥3 yr
Children ≥3 yr
Children ≤3 yr
Females ≥12 yr
Immunology IgG level
Antinuclear antibody 
Antismooth muscle antibody 
Antiliver kidney microsomal antibody 
Antineutrophil cytoplasmic antibody 
Antisoluble liver antigen 
Soluble interleukin 2 receptor 
Children ≥3 mo
Children ≥3 mo
Children ≥3 mo
Children ≥3 mo
Children ≥3 mo
Microbiology HSV DNA
Enterovirus DNA 
CMV DNA
EBV DNA
Varicella DNA
Adenovirus DNA
Parvovirus B19 DNA
Toxoplasma IgG and IgM 
Hepatitis A IgM
Hepatitis B DNA
Hepatitis C RNA
Hepatitis D antibody
Hepatitis E RNA
HIV antigen and antibody
Respiratory virus panel by PCR
Blood culture
Children ≤3 mo
Children ≤3 mo
Toxicology Acetaminophen level
Continued ...
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authoritative the prediction, the less likely 
it is to be realised because the prediction 
itself modifies behaviour.[12] In essence, 
any predictive model of outcome will be 
undermined by its own success. This may 
explain why the greatest predictive power 
that each of the current models attain is with 
the first cohort to which it is applied. 
Another concern about the available 
predictive models is that they tend to lack the 
ability to account for the dynamic nature of 
disease progression. The serial application of 
a model during the course of illness has been 
attempted using PELD scores, but this accounts 
for a very limited portion of the overall data 
used in managing a patient.[13] There are also 
concerns specific to particular prognostic 
tools. For example, the Clichy criteria demand 
the presence of encephalopathy, which may 
only be an immediate premortem occurrence 
in young children, if it appears at all.[14] The 
KCHC failed to stand up to scrutiny when 
applied to the PALF cohort, although Ciocca 
et al.[15] suggested that the KCHC performed 
well in a group of 210 children from South 
America above 1 year of age.[16] In Denver, a 
LIU score was devised based on total bilirubin, 
prothrombin time/international normalised 
ratio (PT/INR) and blood ammonia; 
it was a good predictor of death or liver 
transplantation for children with ALF, but 
on close examination it was far less effective 
at predicting death than it was at predicting 
survival after transplantation – seemingly a 
self­fulfilling prophecy.[17] Recently, advanced 
computing techniques have been applied in 
the form of artificial neural networks, and 
as the predictions made by such a system are 
continuously refined by further data inputs, 
it may be hoped that the evolving changes in 
care will be reflected in updated predictive 
models.[18] Another approach is being actively 
investigated in the PALF collaborative using 
Bayesian mathematical methods to model 
dynamic networks of plasma cytokines in 
order to identify patterns predictive of spon­
taneous survival or eventual death in those 
not transplanted.[19] 
Extracorporeal support 
of liver function
Extracorporeal liver support, analogous to 
renal dialysis, has a substantial history of one­
off experiments, preclinical trials, uncontrolled 
clinical applications and an occasional 
controlled study, but proof of effectiveness 
has yet to be clearly demonstrated. Experience 
of cross­circulation and extracorporeal 
liver perfusion from the pretransplant era 
demonstrated the effectiveness in terms of 
waking patients with ALF from advanced 
coma and stabilising haemodynamic 
parameters, but as soon as the treatment 
was discontinued, the patients deteriorated 
again and ultimately no survival advantage 
could be demonstrated. With the advent 
of liver transplantation, such approaches 
have been considered, not to prevent the 
need for transplantation, but as potential 
bridges to transplantation. Techniques that 
have been tried fall into two basic groups: 
toxin removal, and more holistic attempts to 
restore global liver function (detoxification, 
excretion, hepatic synthetic function, etc.).[20]
Toxin removal techniques range from 
exchange transfusion, plasmapheresis and 
haemofiltration through charcoal columns, 
to modularised recirculating albumin 
dialysis or plasma exchange. None of these 
techniques, though quite widely applied 
clinically, have been demonstrated to benefit 
survival. 
Biological or bioartificial systems of liver 
support include human and xenogeneic 
extracorporeal liver perfusion and a number 
of bioreactors seeded with hepatocytes of 
human or porcine origin, or immortalised 
hepatocyte­like cell lines. Anecdotal descrip­
tions suggest improved function, but the 
methodological challenges in designing 
and powering studies, not to mention the 
difficulty funding them, has meant that any 
promise is as yet unfulfilled. The closest 
anyone has come to proving clinical efficacy 
was the study by Demetriou et al.[21] However, 
the ‘bioartificial liver’ used in this study has 
not appeared as a commercial product since 
this study was reported 10 years ago.
Transplant work-up and 
organ availability
Owing to the vagaries of deceased donor 
allograft availability, once the decision to 
consider transplant for a patient in acute 
failure is made, the work­up and selection 
should be completed as rapidly as possible. 
This can be achieved in select centres in 
a matter of hours, but in order to do so 
without mistakes or corner­cutting, and 
to maintain compliance with the ever­
increasing regulations, considerable planning 
along with the need to establish protocols is 
required for such emergency situations. 
Many countries prioritise allocation of 
livers to children and to patients with ful­
minant failure. In the USA, national sharing 
of deceased donor livers is available to 
patients listed as status 1A. For children, the 
use of technical variant grafts is important to 
facilitate emergent transplantation, and the 
willingness and ability to cross blood groups 
for ABO­incompatible liver transplantation 
broadens the potential donor pool. 
The median time from being listed for 
a liver transplant to being offered a usable 
organ is between 2 and 3 days in the US, 
but there are times when the wait has been 
considerably longer. Living donor trans­
plantation may be seen as a potential 
solution for this dilemma; however, it also 
raises concerns of its own. Can a thorough 
living donor work­up be carried out safely 
in an emergency? How do teams avoid the 
possibility of donor consent due to feelings of 
guilt, duty or overt coercion? However, as the 
experience in Asian countries shows, and to a 
lesser extent our own experience, living donor 
transplantation in emergency situations can 
be both feasible and successful.[9] 
Auxiliary 
transplantation for ALF
The concept of leaving a portion of the native 
liver in situ when liver transplantation is 
undertaken, with the expectation of native 
liver regeneration, is extremely attractive. 
The history of this procedure stretches back 
to animal experiments in the 1950s and 
human experience starting in 1964, although 
success was elusive until the 1980s.[22] The 
Table 2. (continued) Diagnostic work-up for infants and children with acute liver 
failure 
Age for testing
Urine Urinalysis
Urine culture
Urinary organic acids (including 
succinylacetone) 
Urinary copper quantitation 
Urinary toxicology screen
Children ≤3 yr
Children ≥3 yr
Other studies Abdominal ultrasound
ECG
Echocardiogram
PT/INR = prothrombin time/international normalised ratio; BUN = blood urea nitrogen; AST = aspartate aminotransferase; 
ALT = alanine transaminase; GGT = gamma­glutamyl transpeptidase; hCG = human chorionic gonadotropin; 
IgG = immunoglobulin G; HSV = herpes simplex virus; CMV = cytomegalovirus; EBV = Epstein­Barr virus; 
IgM = immunoglobulin M; PCR = polymerase chain reaction; ECG = electrocardiogram.
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majority of recipients of an auxiliary liver graft can be expected to 
have regeneration of their native liver, and it has been estimated 
that two­thirds of long­term survivors will eventually be free of 
immunosuppression. Once native liver regeneration has been assured 
by biopsy, computed tomography volumetry and hepatic scintigraphy, 
a patient can gradually be weaned off immunosuppression and 
the graft will involute. Occasionally, acute rejection, hepatic artery 
thrombosis and graft infarction may occur with over­aggressive 
withdrawal of immunosuppression, necessitating surgical removal 
of the allograft. 
Despite well­described series from centres around the world 
achieving survival rates equivalent to those of other forms of liver 
transplant, there has not been widespread uptake of the technique. 
Reasons for the lack of enthusiasm for this approach have not been 
formally stated, but probably relate to the additional complexity of the 
technique and its limited applicability. Right or left hemihepatectomy 
is required to create space for the allograft, which is challenging in a 
patient with coagulopathy and the need to maintain good cerebral 
perfusion pressures throughout the operation. 
It is generally accepted that auxiliary transplantation is not a good 
option in the face of raised intracranial pressure or haemodynamic 
instability, and technical considerations tend to preclude it in the very 
young. In the King’s College Hospital series of 128 liver transplants 
in children with ALF, 20 received auxiliary allografts and 14 of 17 
survivors had native liver regeneration.[22] Kato et al. also reported six 
cases in children with 100% survival, but only one patient had been 
weaned from immunosuppression at the time of reporting.[23] 
Conclusion
ALF in children is as challenging as any field of clinical medicine. 
The advent of liver transplant and the continuous improvements 
in outcomes have meant survival for many children in the modern 
era who would previously have died. However, the decision to 
transplant or to wait remains fraught with uncertainty. We still lack 
the tools to accurately predict which patients will survive without 
transplantation. Truly functional liver support is not available to 
prolong the period of observation during which more precise 
diagnosis may be possible, allowing a clearer sense of the individual 
disease progression to become apparent and more time to find a 
good allograft if the need for liver transplantation becomes inevitable. 
Auxiliary liver transplantation, although conceptually very attractive, 
is available in few centres and is only feasible in a small proportion 
of potential recipients. Careful clinical judgement remains our best 
defence against children dying from ALF for want of a transplant, and 
the occasional unnecessary transplant in a child with ALF who might 
have recovered without transplantation.
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